Achillion shares jump on positive interim results from ACH-3102 and ACH-322 for hepatitis C
US pharma company Achillion Pharmaceuticals (Nasdaq: ACHN) saw its shares jump as much as 60% on the announcement of positive interim results from ACH-3102 and ACH-3422 for hepatitis C.
As part of the mid-stage trial, 18 treatment-naive patients infected with genotype 1 HCV patients were randomized to receive treatment for six weeks with the combination of ACH-3102 and Sovaldi (sofosbuvir) manufactured by Gilead Sciences (Nasdaq: GILD), or observation.
The ACH-3102/Sovaldi combination resulted in 100% sustained virologic response four weeks after therapy ended. Achillion will disclose the data to show if sustained virologic response at 12 weeks, the primary endpoint, was achieved in the first half of 2015. The combination showed no serious adverse events.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze